- Earnings call transcript Q3 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon. And welcome to the Albireo Pharma Third Quarter 2022 Earnings Call [Operator Instructions]. Please note that this conference is being recorded. I will now turn the call over to your host, Hans Vitzthum, Managing Director of LifeSci Advisors. Thank you.

begin. may You

Hans Vitzthum

is This its operator. the issued press press a quarter site company's Thank albireopharma.com. at business afternoon, accomplishments highlighting release This XXXX. recent September for via and release the ended Web you, XX, Albireo accessible financial third results

be they proceeding, like the Private are not statements section and that accessed statements. factors, no of or Actual risks of upon of being under the the at the to publicly in Before Litigation various our management's most albireopharma.com Web include views Reform may represent XXXX, section XXXX, undertake SEC’s Risk These today and from those company's should we including to be materially dates. subsequent and subject Form subsequent recent SEC can regarding statements expectations. would the Investors these Securities on and Act Any may and forward-looking November Factors described results update We X, obligation as our important the due views any note to comments relied are company's XX-K plans made various forward-looking site. today, as to statements uncertainties. of representing filings. filings as These differ

Now President to to and it is turn Albireo's my over Ron Chief Ron? Cooper, pleasure the call Executive Officer.

Ron Cooper

quarter, product Albireo of reach continue data Officer and the both clinical Financial also Head significant in this develop me Officer; to to Meeting for its is top as diseases. on today With our quality value which and present more access Chief excited of front AASLD joining Pamela are on Chief afternoon. this to lead and past patients exciting at Revenues front. Musin, to been We're Hans, moving Officer. Liver us and strengthen Thanks full have we Jan as this Chief you we another to gaining Harford, our weekend. the all Scientific for thank Stephenson, quarter Bylvay accelerated Simon new potential. Dr. anticipate the It's fast the commercial additional evidence The Bylvay, Commercial R&D; our We're

Let studies. data to over give on our and it me you Jan the update an turn to

Jan Musin

that Thanks, Ron. AASLD the to clinical attention two presentations, Meeting weekend breakers a the three your important posters. as improve, specifically symptoms disease very draw that with rich and and we had achievements. natural We Bylvay at modify like native drug the modification study including with have believed six well of be as both Starting the course I liver would late diseases to liver cholestatic would a survival, diseases. always would of three oral

set can As responders bit bile latter, of an acids serum six the liver was now versus data to three improvements X.XXX. value up presented function for remained pruritus it urgency mean All P in of with appreciate, free also and transplant we in bile PFIC had you remained and data at session Full liver a parameters. data we with responders acid with is years. Responders liver all Bylvay that a the native for to associated transplant strongly PFIC. first at bile native non-responders, to oral with PFIC responders moving sessions, In Bylvay serum in three for patients years. of showed to who free generate are months up acid Decrease for treatment survival available. scientific responded but little demonstrating time improved patients in liver takes data survival analysis

Bylvay, demonstrating in as Delivery This and breaking demonstrating selected first future. a we late step just was there Best is category. that the bile biliary Bylvay addition, in native key of pediatric anticipate in in the for In hepatology oral providing a near additional the liver presentation the AASLD by survival with acid was flow Meeting data restored inclusion presentation and

as data last which efficacy month, presented NASPGHAN we children with and supports treating native the Meeting at in could addition, liver. preserve disease Annual in mild the as early greater pruritus In result the possible, even

clinical top data line in X able less submit and the announced data ago, is to time. a AASLD diligently the team study ASSERT. to in the great for Another We Phase R&D worked achievement has month than syndrome ASSERT record to Alagille updated be set

presentation to regulatory beat out As our category. The to a The interesting data positive. the file best ASSERT we presentation, the the set oral from response meeting Europe, key breaking and submissions and selected working late is fast of medical in well, with the was PFIC and accepted -- very team liver our the a submission. community been in in hepatology US as pediatric as record was has by trying

at Bylvay diarrhea rate responders and being X.X% a provide XX% point at over being low also at placebo Bylvay therapeutic placebo dose without can defined in what improved with it combination XX.X% pruritus demonstrated With achieve the Overall and acids study saw For in Alagille Bylvay been improved to studies to can sleep diarrhea drop of inhibitor drug PEDFIC a was in diarrhea a rate group. having with diarrhea related patients cope across patients age many X of of similar first reduced work the the the X most was the time, relief a group IBAT pruritus, as XX.X%. prominent our at Phase levels. an and to patients study to time has any we least genetic with Drug in with sites wider bile the we in two during related low of low high so as and X.X% treatment-emergent that syndrome rate. with the point,

X conducted the pandemic. trial of XX Finally, sites our exceeded XXX with world according fully during cholestatic into to now enrolled in around their XXX versus our big X ever public and I'm target across biliary hard children work guidance. Phase enroll global proud COVID the for largest study organization our pediatric R&D Phase to their are the BOLD determination who atresia We the and

requirements. have positive and had decided common as We atresia discussions meet recent studies X and given the and look Phase bodies our our top to data outcome disease in in feel Biliary line approval we is of confident readout try to Alagille regulatory liver a most extensive XXXX. with PFIC success with and pediatric syndrome, Bylvay to forward a

in So liver looking and improve share It's that data to I'm forward patients, PFIC to I'm Ron? atresia can to Alagille patients. in supporting survival evidence pleased you Bylvay conclude, with native effective patients. new Bylvay in biliary

Ron Cooper

low has of only Bylvay dose, scientific with term evaluating that drug diarrhea types, low differentiate across the combined syndrome be now a roughly Bylvay once Alagille clearly Bilbay is the inhibitor Developments unlike combined. for as IBAT related is trials, easy a show efficacy PFIC, in or therapeutic and PFIC Bylvay X IBAT in and size two PFIC rate administered only sprinkles PFIC studies in one a to X demonstrated in food little the But day opportunity a studies. could Jan biliary a the With above atresia, atresia. Thanks, given in placebo has Bylvay Phase capsules for to Alagille controlled best-in-class including all liquids. update. IBATs, is and inhibitor. Great. And that’s placebo Biliary or other a long third

seeing we study. market a does patients broader What that is already approval patient a in a this addressing means in PFIC, first We're launch PFIC types for stellar to a positive convenient for Bylvay mutation supporting its excellent tolerability, many We Alagille population BOLD with in expect of syndrome. means? the excellent potential Bylvay with across QX. and clinical with an outcome It all data the this product have approved be to

Pamela? the turn So details over me provide it more Pamela let to to on quarter.

Pamela Stephenson

everyone. Thanks, good afternoon, and Ron

which further delighted the more are XX million with are weight in the mentioned patients last than XX XX of previous who reimbursed we launch, rollover time expect for patients, total compared that revenue more generated with on medication a patients, ongoing product tolerability the QX prescribers have sales account color convenience patients see the new total commercial daily with now world. normalizing its treatment, patients only XX% drug over FDA and disease. increased annuity of variability Today, inline is rate drug another up comparable for profile. the are the revenue what expected. $X.X its be and the rare discontinuation front. the to the Bylvay's in XX and seeing The the PFIC is are I'll XXX. reimbursement future. its the continuing benefiting with to The and global with Revenues patients, pending we patients on Bylvay XXX a These starting to see X.X rates quarter. number by favorable products with observed We have quarter. we're to on of in XXX and We the administration around easy advantages for Overall and as net and and We patients Bylvay we and more first in benefits caregivers approved of is giving patients share families trend we our with efficacy of expectations once million

demand on in see delivering world especially HCPs is make believe our generation capture inline speed are clinical and and than scientific exchange that it and better optimal. excelling promise product, this real product patient in we Bylvay again, has where a business, even the reimbursement, and growth. execution global on And international and Europe or on the what revenue with you was in and our into translate start Let's the use Furthermore, been see pricing seen trials. to

to grow ratings This and five product markets, and atresia. in Bylvay’s continuing UK, with in France. Germany, serve platform will strong receive plan continues the health as as the recently European our European Alagille well modification unique our technology market in rapid AASLD. demonstrating Italy, as its syndrome disease biliary we just reimbursement in our well Europe potential us Europe are on to Bylvay based clinical believe drug at We from are as early high and approach, eventually tolerability. Phase by in as and to Belgium confirmed European our to understanding payer liver and launch in Bylvay results, benefit, favorable label HCPs preserve demonstrated presented X term its long in data sustained liver trial a native assessment in

Let's look at take a the US. closer

in work of relentless in the the We are seeing field. increased an because mostly US, our demand

We XX to total increase unique prescribers the continue adding XX. of bring to number new prescribers quarter since QX each HCPs to in steadily unique our launch,

urgency understand success symptom treat the HCPs We with have how liver underlying accounts in treat a and act had their to Bylvay can disease where the the patients. most PFIC of

even immediately programs to resources understand base. accounts treat MSL mild force result, where This up strong allocation and importance help a prescriber and need of to treating aligning the are our pruritus help should accelerate disease education to continue deploying and US we As our in clinicians dialing urgency US sales to cases. resource additional we expanding

Bylvay is our of progress, PFIC another for the the following As launch syndrome, preparing company launch Alagille time this impressive continues Phase to X data. for

to market with excited the PFIC, have had share benefits from all worth and that opportunities total $XXX physicians up larger eventually are somewhere ongoing meetings the points Furthermore, million prescriptions us same and authorities, biliary in market learnings into they should every XX are than Alagille which PFIC are leg between The $XX the in the believe to atresia. dialog to patients we and and indications syndrome In payer translate anticipate We opportunity what million. treating take is in global for for major in reimbursement PFIC Alagille. a of and we both and launch. seeing gives Europe, the is

pricing patients will Alagille real able to of has patients gain other entrant, We valuable share. position in expect inhibitor, across the indication. and for overwhelmingly US, that the being I been the as similar expect with reimbursement positive, in experience to countries different types close we our a to life capture are PFIC a access a an market even patients and European to and by as strong physicians second be IBAT already giving most forward at time saying launching looking more we many to

the to cover review. I'll Now to Simon Simon? call our over hand financial

Simon Harford

Thank Pamela. you,

million our third XXXX. revenue US revenue the in summarize for was last $X.X million me results quarter of financial $X.X in was global million. and same $X.X was million the the $X.X year. net Let revenue international Bylvay from quarter, product quarter up

the will we As there on forward are year, repricing international be period the we of of to QX as outside impact an look Germany. sales end months the now XX in

The which compared of royalty for pleased with $X.X We of the of relates Partners. Royalty the to with a million leaving quarter. passed being estimated $XX with are million. $X.X for the same XXXX QX, of the was the revenue million revenue, in was revenue Cost very prior for in to revenue resulting million revenue Bylvay decrease million. million HealthCare Royalty guidance period quarter and XXXX but XXXX third at year XXXX, $X.X is product time on the compared quarter $X.X in decrease third of $X.X in

Bylvay the were current prior QX, loss of and certain $XX.X reporting headcount share net quarter of due $XX.X compared was from all personnel no our related material $XXX.X were materials priority royalty annual to million. of continue single We with indications amount was is These Research attributable in million are support digit basis and global products proceeds million net three net royalty Bylvay. global a for a average with or in included administrative upfront the if per sold force to Sagard income entered Partners the return voucher and billion approval. dollar additional and the resources quarter development on develop in $X.XX a in was treatment to total additional as as expenses commercialization for clinical $XX.X revenue. There were monetization in further income and or $X.XX X net increase Bylvay million. share increase ‘XX XXXX principally September of rate of increase activities quarter development three in the product efforts. were are XXXX, period of the research to approval million Following we as million months including $XX.X increase expenses to now XXXX expansion loss quality financial XXXX. in million us a of approved. of the expensed for due of related and Bylvay, for third is the compared to a income costs million same manufacturing mid for agreement an headcount the cost fully $XX.X XX, with rare purposes. Net to to general of for and year September sale diluted Bylvay treated to diseases. for revenues for million Selling, our for expenses provide third sales costs related an $XX.X the means on cholestatic of The ended last of $X to liver into time product for per into $X.X a compared for The Healthcare The activities. program QX expenses review Net debt agreement third increase

had of is the As recorded balance sheet cash than to the interest as equivalents liability upfront income interest a result, only The and statement statement. on impact proceeds income revenue cash The let the Ron expense million rather under total company from data With the $XXX.X in extend and the related readout expense. biliary projections. it cash XXXX, back the XXXX. the net company cash, BOLD me based revenue fee of September least of our to are restricted to at closing this line be beyond top expects in runway current that, atresia turn on for to our remarks. The XX, sufficient study

Ron Cooper

sales, in you, PFIC to atresia key solid we clinical billion disease This have our liver two product second strong cash total PFIC making medicine the from the increasing X with Alagille the to for a ongoing Thank a Bylvay and third to to successful Bylvay, Bylvay Phase on Simon. pediatric syndrome with half and leading drug best-in-class us place drive With company dollar of Phase strong a quarter puts patients stellar X in the profile steady aspiration of be cholestatic in another position, studies data. enrolled, a take a drug. decade, Bylvay fully biliary now a a continue pace and in

strong and position to drivers. trials tremendous continue open have portfolio on opportunity assets growth early respectively. joining remain and Q&A. liver and for to our AXXXX, for X We will our and pleased we thank The Phase in will with financial us Operator? which the a into everybody Phase We X focused now AXXXX go and progress call disease adult

Operator

Instructions] Eun of [Operator comes Yang Jefferies. question from first Our

Miriam Nolan

Eun, for question. taking This is for our Nolan thank on very much you

on one atresia, have biliary We please.

heard be reasonable only as option. it most transplant liver Bylvay we've get the an used curative to So to that would gap to that patients Is pediatric assume bridge transplant? liver

Ron Cooper

are these And First, the about we biliary are children about with right you have BOLD treatments think enrolled. it's really have are excited the available. getting ask pretty their fully in and pediatric when then trial cholestasis. terrible the is parents study atresia, procedure. there largest they This now, because And right, for what no available, these families, treatments they baby, will this

the in And only is towards thing transplant. the they look so future a can really sometime liver

we that are families either is hope even even for delaying that And to so what healthier course, transplant. hoping the children Bylvay that So preventing those and with or those potentially who’s we child changing bring by a transplant right?

data looking getting in So forward we that XXXX. are to

Operator

Our next Brian comes Baird. from question of Skorney

Brian Skorney

to look Just in you corporate kind patients, patients. of reimbursed want have deck Bylvay the in numbers at your terms that

So I quarter a of the back I'm sort just like of the patients quarter. at the of up of reimbursed sort at wondering of of matches price, it coming if each -- the last look out net with do against the the calculation envelope expected next end sort of kind launch

represent revenue? of in it us of right the understand, to help stepwise X.X about reimbursed I guess Can at for projecting think patients way X.X, if those out quarter you that rolling So terms like is XXX the fourth kind based imply would on X.X kind what of look I sort of of quarter. this

Simon Harford

a teenagers, many and of terms of more have trends widespread point basis have six individual times, obviously, we way children in as up Brian, you to on revenue, launch. still everything quite to discussed correlation, direct have the What an all say old for direction at of of particularly it the sort I a this from month it in travel which is future is would is not the you, revenue, that indicator

So there help upward going will to are variability in an you be certainly, some understand overtime. is trend we But the that from direction time-to-time. there

Brian Skorney

of your then maybe a sort variability. to just on point And follow-up that

that sort As we sort it's reliable think at you net first do patient under of and of consistent see Do pricing of sort patients choppiness are reimbursed, couple you of point more get saw per more quarters? that a over you of more the a sort we average? where

Simon Harford

So there be I of mix, ultimately you of reliable, the still of a for say sort not because way average greater I maybe go. road a is revenue couldn't think it's along quarters right in becoming sort some more to should little critical things are mass out bumpy put it that's terms overtime extent. But the from to the bumps few should to

Ron Cooper

Thank look reflects versus what Implicitly, XX that, you Brian. difference, value times the to you it's and about at right? between Simon that's if for a So kind really the that speaking is of variability questions, the child teenager when a quarter-to-quarter. adult, tenfold

Operator

next comes from Baral Ritu Our of Cowen. question

Ritu Baral

that the for might ask condition. a Can as their mean be the their you drug liver serum good to as that what it was it intriguing Bylvay on -- [Technical especially Thanks last And acid might partial wanted US I survival? could across data might prolong clinicians Difficulty] survival pretty presented cholestatic what you to to to that the for it versus physicians at the mean this you the was and for drug and liver pruritis perspective talk about potential conferences what weekend. It bile taking responders. your question. see --

Ron Cooper

Ritu, pleasure as see to well. you

saying? -- were and does bit, you’re is and it, little do do kind that prescribers what you liver but presented in you chopping will of I we US that what were out right? what on a mean how data the they building that on Is that think native with survival You saying they think PFIC, will to how

Ritu Baral

given the dataset. responder of class that Yes, especially part as partial

Ron Cooper

responder the around different is geographies. think Phase some I So types different it's find it's patients And in has with really physicians were that's Bylvay data. but There understand symptoms, is excited about the was we responders you at when data past right? what responders same improve net often the not if is to utility smart look And that responders, responder do I of where compelled a livers expands difference there's this that if help these partial world, and particularly same X patients, what's when the presented time the doesn't a it's preserving interesting you're potential responder. partial also no X that their matter things. definition. a to that really And they is created partial get the think we remember over really only The partial definition what full to of what responder or the full weekend, definitions PFIC the pretty did, is, definition, it the really we've between

You pretty data based this do liver your the survival well seem PFIC weekend. on to with we past in native presented

Ritu Baral

to is change take to pretty FDA you that can mean, it I was presentation. a And language? that label compelling something

Ron Cooper

Yes, the compelling it for presentation. Thank a you was It complement. was.

Jan I datasets in other comments, think is on. that prepared just has and first as of working creating the this we're said the

a reactions a there. where we'll data we'll dialog get think, with these it as given time mature, take their into to authorities, there'd I So data and regulatory sets be from the

Operator

comes of Guggenheim. from Our next Fernandez question Seamus

Seamus Fernandez

the excited in likely the to with seems on So on see one about who there progress just a established necessarily in It not in what secure competitor reimbursement you stage are to terms that pipeline, earlier the opportunity maybe bit is planning question just little and to pipeline Europe, indication, you’re question particular, in to you guys markets, on potentially going update how those Alagille to you with in is of particular, and of stage an are the Ron, the in kind like the and most the for pipeline? see you indication? we is products how earlier data us the the when you in opportunity be bring reimbursement. capitalize second market earlier but is, market prior reimbursement And can as and

Ron Cooper

first Actually, maybe let Europe, evolving. pipeline and on the how see we little I'll a comment I'll then talk first question Pamela bit in about regards to the

So Pamela?

Pamela Stephenson

say -- have have of lot that assessments payers first the assessments high been would given, have we of we with with clinical asking. know The and is, a we experience questions thing be Europe are in sort I that the and experience just and they'll pleased

as head the terms we think clinical pricing contracts certainly ratings to good us dossiers in in And being gives needed that's reimbursement a of the we payers. and these secure this advantage high So many into to Alagille, type of with able submit place of to have quickly the favorable we need get large already reimbursement.

And expect process quite go to smoothly. that and quite well so we

Ron Cooper

good if kind think there about place PFIC in as and ratings data. the great We We we're going ASSERT European with And data, of contracts Seamus, by just X, countries received, countries. already indications with I time Phase said, the most add, looks that you would with Pamela really these place-by-place, have which well. in

We have place. quickly should in force a there. pretty sales go to be able We

as So and to first these we ASBT having only drugs, that. anticipate year. we’ll oral Phase think what be data right? only we’ll a next it is be some study. forward inhibitor. world's the the are And is AXXXX, going early AXXXX AXXXX, X Phase first the a study. AXXXX NTCP going X we into pipeline, and into about, stage Then are relates real excited I we look to inhibitor. systemic world's

don't so we're just a what job Jan long excited these team advancing the products. and And ideas, pretty is go, great but done drugs in have were about these

important going into about are awful tell an really medicines. some potential lot We for the these that studies are us coming to new

Operator

Lugo from question Tim of Our William Blair. next comes

Tim Lugo

is this. I before believe know guess maybe that mentioned I therapy. And is it But just will expand versus liver pointing give see do a that, of the around And therapy the as frame us, comes presenter, Bylvay everything just year, this just this this modifying only what is is upon maybe a timeframe, direction. kind the in time maybe I survival you believe? quote kind truly that data that year therapy. community Can data, we was, in some the I what's is disease before modifying is like expanding time around just viewing tell more with agree you symptomatic working Jan disease timeframe? a guess, as you the of to maybe on a the on one Can two sounds communities the presenter truly

Ron Cooper

think, long question is is when this you're in this always is I longer this the real think, the scientific I But these case, meetings, like I better. always you which very know think question classic will a able right, or that reverse show at liver frame. time be we anybody don't disease, right? And if is I a high over to bar, will

as in more a think, members goes really believer data that is this native be have the we important liver we survival. improve show that So and believe the we that's that know are sort we I time, many fact, that data community well. is that of that this in three have given over the years presenter should ultimate, data in right? now case we'll data I strong think, -- that I to And of

it's we're modifying that's right, To know believe a don't we the important. most that, So that's to the going reversing be doing going I disease, and be if disease. anybody's high. be to very what's to say, able you're bar

Tim Lugo

to But there early guess the those pending just months? on that still a launch. reimburse those any And into we're more XX of patients it I launch, beginning XX kind we go of like the of patients I should has since patients are reimbursement. assume eventually or been leakage know sounds commercially number certain over will just therapy the talking, of

Pamela Stephenson

history don't final patients assume can on patients has to countries reimbursement have are yet have patients get will those leakage. reimbursement. literally we to countries Those in date our where that transitioned. been no those we And the You There's go been therapy. that in when

Operator

comes Argyrides Our of Andreas Wedbush Securities. next from question

Andreas Argyrides

more the prescribed then still follow patient PFIC, Bylvay growth have where and do for a see younger Are being we you mentioned from? recent normalizing. as in weight and impact So I is coming seeing And biggest you patients? And that up.

Pamela Stephenson

seeing weight, patient with patients your what I if So we're correctly we're younger is question seeing is understand so a older and patients.

seeing over of will overall we're individual patients the of the number Bylvay. And to of the And sort patients overall, is patients good on of fluctuations will the impact increasing, sort coming increase. subside of the of So Bylvay a because revenue number of time. variability

Andreas Argyrides

competitors the Alagille launched syndrome. Ron safety the with or as would year And standard it diarrhea on difference When the data, one US likes under say, in to switching? we population, and old the meaningful EU? from when in gold encourage differentiating those Is strong Bylvay

Ron Cooper

first see controlled think community data. Meeting the the Phase that. is reaction first And if I this and all, they're have placebo Well, time take at both past this international X the the of week, you the data, and US Liver randomized excited pretty to Andreas, of I the that AASLD

always fact that it's it's the if itself, or mixed I or as a and I it's once-a-day, that PFIC as can food XX.X% the capsule we your were physicians, So it's on and talk we in think what's being drug across Andreas. that Then overtime. Bylvay it And they It's it's one the with wider the thing, there point tolerability, throw physicians. was and that just we that very range the X.X% multiple of absolutely mutation that at a were that about what delighted sustained things. the water, that's top dose, then capsule the database, the not once, patients exciting put don't fact saw types to physicians things well, that the mixed of totality a this it's consistent are It's a on you So database. the seen fact look it's group diarrhea, driving. of And you be is low range international that US effects with the that placebo that are one both taken early and package in with When with thing, the of the are to just you think patients. the a both together right? in It's fact the group.

Operator

of Our next Wainwright. question comes from H. Ed C. Arce

Thomas Yip

Thank asking is couple questions. Ed. a questions couple a taking our Yip us. of from for Perhaps for This you Thomas

aspects for would areas? as you what EU, the two approval Bylvay’s most a potential commercial in important Assuming highlight US and those and launch

Ron Cooper

I previously, of Thomas. bit A what before little said

X I patients, breadth and There sustained data, that are rate depth unequivocal wide think data different of different of of data the and range just mutations, across Phase it's patient effect. types. sort

or be in So itself, of capsule to then the in liquid what what's tolerability dose, qualities and think profile profile. And once attractive. We implicit the or and reasonable about. give a low that's speak with drug going a very just best-in-class always the I that day, to is easy we'll food, always the that's a think

Thomas Yip

in anticipate other look one question then investors And larger the there’s How and at in enrolled. combined? market outline major even the biliary two much Alagille you versus a strategy opportunity differences should atresia Can indications? perhaps for to commercial PFIC that as [completely] biliary both mentioned [indiscernible] atresia with market you some compared you

Ron Cooper

the that that Alagille and PFIC in a Europe covers for our out it's it for beauty very doctors covers prescribe about well. built commercial business model, it, really you and Well, that for biliary the atresia. structure Thomas. audience think US the and When that's same We of

get are not resources these we much to going So incremental customers. require to at

which that's can opportunity, our for we biggest to business. And as so becomes the really that, as said biliary atresia, you take right? us, accelerate is changer game we It really a get

Thomas Yip

progress forward and looking you Got regulatory questions, filing. it. Alagille Thank our again taking in for to

Operator

over We turn closing call for Q&A of have remarks. end Ron the now session. I reached our to the will

Ron Cooper

their operator. attending employees today's as I and of organization's for to every planned. and thank And each ability you, deliver I'm one our proud of call. you really all our for commitment, Thank and families as execute conference Thank Great. drive for liver and updated diseases. Thank Albireo’s innovation. Continue impacted mission to these by keep you your continued to you devastating support. all patients to provide hope advance we

Operator

today's concludes This conference call.

You Thank participating, pleasant day. for you have may disconnect lines. and a your

Albireo Pharma (ALBO) 9 Nov 222022 Q3 Earnings call transcript